Release testing answers "is this lot what the spec says"; stability answers "for how long." A strip release panel is appearance, dimensions and weight, moisture or water activity, seal and coding, potency, content uniformity where the dose matters, and micro. Shelf life comes from real-time data at 25 °C/60 % RH; the 40 °C/75 % RH study is an early-warning tool, not a substitute.
| Test | Reference | Typical limit or note |
|---|---|---|
| Appearance, dimensions, weight | Spec | 22 × 32 mm; weight per unit against target |
| Moisture or water activity | USP <1112> | Water activity below 0.60 blocks growth of all listed organisms |
| Seal integrity and coding | Spec | Visual plus dye or vacuum leak on a sample |
| Potency | Validated assay | Against label claim |
| Content uniformity | USP <905> | AV ≤ 15.0 on 10 units; 30 units if needed |
| Microbial limits | USP <2021>, <2022>, <2023> | TAMC ≤ 10³, TYMC ≤ 10² cfu/g; E. coli absent in 10 g (non-botanical) |
| Disintegration | Method written in spec | 30 to 60 s target; USP <701> not suited to films |
Release and shelf life are different questions
A release specification is the lot's pass/fail list, tested before disposition. A stability protocol repeats those tests on stored samples at set pull points. Write both before the pilot is cast, with a method and a signer for each test. Our standard is the same core panel on every lot, third-party work through ILS Lab, and one Lot Release Packet per lot.
The release panel and the chapters behind it
Potency is an assay against label claim. Content uniformity follows USP <905>: ten units, acceptance value not more than 15.0, then thirty if the first ten miss. Micro for supplements is USP <2021> and <2022> judged against <2023>: TAMC ≤ 10³ cfu/g, TYMC ≤ 10² cfu/g, E. coli absent in 10 g for non-botanical products.
Disintegration: the number nobody has standardized
FDA's ODT guidance uses about 30 s in vitro as the benchmark; Ph. Eur. asks only that orodispersible films "disperse rapidly"; reviews use not more than 60 s. The USP <701> basket was built for tablets, and a 2019 comparison found it a poor predictor for films, while a cell method matched in-mouth times at R² = 0.999. Our target is 30 to 60 s. Write apparatus, medium, temperature, and endpoint into the spec or the number means nothing.
What "accelerated" actually means
ICH Q1A(R2) sets long-term at 25 °C ± 2 °C / 60 % RH ± 5 % for at least 12 months and accelerated at 40 °C ± 2 °C / 75 % RH ± 5 % for 6 months, pulled at 0, 3, and 6. A "significant change" there (a 5 % assay shift, a degradant over limit, or a failed physical or functional attribute) triggers an intermediate study at 30 °C / 65 % RH. Accelerated data support a provisional date; real-time pulls confirm the 24-month target we develop toward. ICH also notes moisture is not a concern in impermeable containers, which is the case for a foil sachet.
Water activity as early warning
USP <1112> lists what each organism needs: about 0.97 for Pseudomonas aeruginosa, 0.86 for Staphylococcus aureus, 0.77 for Aspergillus niger, 0.61 for the most xerophilic mold; below 0.60 nothing grows. A strip at 4 to 7 % moisture usually reads well under 0.60, and a rise across pull points is the first sign of a leaking sachet.
Worked example: a 24-month plan for a melatonin strip
A hypothetical brand, Harbor Sleep, wants "best by 24 months" on a 3 mg strip in foil. From the 15,000-strip pilot: 40 °C/75 % RH pulls at 0, 1, 3, 6 months; 25 °C/60 % RH at 0, 3, 6, 9, 12, 18, 24. Each pull: appearance, weight, water activity, disintegration, melatonin assay; micro at 0, 12, 24. Thirty sachets per pull over eleven pulls is 330 sachets, about 2 % of the lot. Limits: assay 90 to 110 %, water activity ≤ 0.60, disintegration ≤ 60 s, no seal failure. A clean 6-month accelerated result supports a 12-month provisional date; the 24-month claim waits for the 24-month pull.
Questions for the manufacturer
Which tests are in the panel and which cost extra. Who chooses methods. Who pays for repeats and how an out-of-spec result is investigated. What arrives with the lot. Who stores stability samples and is responsible for the pull calendar.
Common questions
Not on its own. It supports a provisional date and flags problems early. Real-time data at 25 °C/60 % RH confirm the claim.
ICH asks for three primary batches for a drug application. For a supplement pilot, one lot on a full protocol is a defensible start, with each later lot added at a reduced pull schedule.
Primary sources
- ICH Q1A(R2) Stability Testing of New Drug Substances and Products
- FDA Guidance for Industry: Orally Disintegrating Tablets (2008)
- Disintegration time of orally dissolving films: methodologies and in-vitro/in-vivo correlation (Pharmazie, 2019)
- Orodispersible Films: Current Innovations and Emerging Trends (Pharmaceutics, 2023, PMC10747242)
- USP <1112> Application of Water Activity Determination to Nonsterile Pharmaceutical Products
- USP <2023> Microbiological Attributes of Nonsterile Nutritional and Dietary Supplements
- USP <2021> Microbial Enumeration Tests, Nutritional and Dietary Supplements
- USP <2022> Microbiological Procedures for Absence of Specified Microorganisms, Nutritional and Dietary Supplements
- USP <905> Uniformity of Dosage Units, FAQ
- US 11,083,734, dexamethasone oral film (6-month 25/60 and 40/75 stability)
Formula feasibility, packaging, testing, claims, timing, and final quantities depend on the exact product. Use this guide to prepare better questions, then confirm the production plan for your project.